Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]-Rigosertib in Healthy Volunteers
NCT02030639Phase 1Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Traws Pharma, Inc. Primary endpoints: Mean percent of the radioactivity of the administered doses recovered in the urine, feces, and overall up to 216 hours, Concentration of rigosertib in plasma up to 216 hours and 2 more. Started Jan 2014; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02030639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030639.